Status:
UNKNOWN
Efficacy and Safety and Pharmacokinetics of Boya IVIG
Lead Sponsor:
Azidus Brasil
Collaborating Sponsors:
Boya Bio Pharmaceutical Group Co Ltd
Conditions:
Primary Immunodeficiency Disease
Eligibility:
All Genders
6-60 years
Phase:
PHASE3
Brief Summary
To evaluate the safety, efficacy and pharmacokinetic properties of Boya's IVIG preparation in participants with PID aged less than 60 years and more than 6 years.
Detailed Description
This is a phase 3, open-label, prospective, single-group, multicenter study to evaluate the efficacy of IVIG in keeping the average number of serious bacterial infections to less than one per year. Th...
Eligibility Criteria
Inclusion
- Signature of written informed consent.
- Men or women.
- Age ≤ 60 years.
- Diagnosis of PID disease (PID) with a reduction in antibody production due to:
- Common variable immunodeficiency (CVID) as defined ESID/PAGID, OR
- X-linked agammaglobulinemia (XLA) as defined by ESID/PAGID.
- Receiving intravenous immunoglobulin replacement therapy at 21- or 28-day intervals at 300 to 600 mg/kg/month for a minimum of 2 months prior to study entry.
- Absence of episodes of serious bacterial infections with prior use of IV immunoglobulin for at least 3 months prior to screening.
- Negative pregnancy test (in female participants of childbearing potential); readiness to use reliable contraceptive methods throughout the study period.
- Patients who have participated in a clinical study with another investigational IVIG may be included if they have a potential benefit in accordance with CNS Res. 251/1997.
- Participants undergoing treatment with any subcutaneous or intramuscular immunoglobulin may be included by switching to IVIG therapy at the discretion of the investigator, considering the possible benefit to the participant.
Exclusion
- Known intolerance or hypersensitivity to immunoglobulins or components of the test article;
- Any contraindications to the use of immunoglobulins;
- Secondary immunodeficiency or conditions potentially causing secondary immunodeficiency such as chronic lymphoid leukemia, lymphoma, multiple myeloma, protein-losing enteropathies or nephropathies, and hypoalbuminemia;
- Clinically relevant changes in the safety exams are defined as:
- Blood count
- Hb \< 10.5 g/dL
- Leukocytes \< 3,000 / mm3 or \>10,000 cells / mm3
- Absolute neutrophil count \< 1,000 cells/mm3;
- Coagulation
- TP and aPTT \> 2.5 x ULN
- Biochemistry
- glycated hemoglobin \> 6.5%
- total bilirubin and fractions, alkaline phosphatase, ALT, AST, GGT \> 2.5 x ULN
- creatinine above 3mg/dl or creatinine clearance \< 30mL/min
- Urine I.
- Leukocyturia \> 10,000 cells/mL
- Any cancer either active or resolved within the last 12 months before screening;
- Receiving any blood products (except intravenous immunoglobulins) during the last 3 months before screening;
- Any febrile illness within 14 days before enrollment; Note: The patient may be rescreened after recovery.
- History of thrombotic events (including myocardial infarction, stroke, pulmonary embolism, and deep vein thrombosis) within 6 months before enrollment;
- Previous use of live attenuated virus vaccines;
- Selective deficiency of immunoglobulin A (IgA) or known antibodies to IgA;
- Known drug or alcohol abuse;
- The need to use other investigational drugs, systemic immunosuppressants, and any other immunoglobulins;
- Pregnancy or lactation;
- Inability to comply with the protocol activities;
- PIDs other than CVID or X-linked agammaglobulinemia
- Patients infected with HIV, HBV or HCV
- Patients with AIDS, cystic fibrosis, or active hepatitis B or C.
- Any other condition that, in the Investigator's opinion may increase the risk of participation in this study.
Key Trial Info
Start Date :
April 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2025
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06150833
Start Date
April 1 2024
End Date
September 30 2025
Last Update
November 29 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.